Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genasense data released

In briefing documents released in advance of Monday's meeting of the Oncologic Drugs Advisory Committee, FDA said that approval of Genasense oblimersen from Genta would require the agency to change its standards for assessing the

Read the full 357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers